Articles On Imugene (ASX:IMU)

Fresh from a strongly supported $35 million placement, ASX-listed immuno-oncology medtech Imugene is on a steadfast mission to activate the immune system of cancer patients to help treat and eradicate tumours.

Telstra Group Ltd (ASX: TLS) shares and Vanguard Australian Shares High Yield ETF (ASX: VHY) are both known for paying dividend income to investors. In this article, I’m going to look at which one could be the better choice for passive i...

By Greg Peel Choosing to Follow On It was a rock’n’roll session on the ASX200 on Friday, ahead of a flat close. The futures had said down -28 on Wall Street weakness, the ASX200 fell -22 points on the open, but by 12.30pm was up 21. Then it...

The pre-eminent benchmark of the Australian share market, the S&P/ASX 200 Index (ASX: XJO), narrowly avoided its third consecutive negative session on Friday. Today’s feeble finish to the week coincides with a financial milestone for C...

The ASX200 had a stronger session than expected, closing up, but only just. The real estate sector led the way gaining 1.8 per cent, utilities were also up by a per cent and materials just short of a per cent. In the green Goodman...

ASX 200 benchmark falls, gains and wanes its way to just 0.03% for the day. Real Estate, resources and gold (oh my!) lead a troubled bourse from disaster. Mining tech minnow Orexplore’s $1.55m BHP deal delivers a +150% gift for investors....

It has been another busy week for Australia’s top brokers. This has led to the release of a large number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here’s why brokers think th...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain on Friday. In afternoon trade, the benchmark index is up 0.1% to 7,154.3 points. Four ASX shares that have failed to follow the market higher today are listed below...

The ASX200 has gone against expectations and lifted ever so slightly by 0.1 of a per cent mid-session. Real estate led gainers – up nearly 1.5 per cent – but the heat was on communications and consumer discretionary which have both shed...

Building a portfolio of ASX shares that will pay you a generous income stream is a hard task. After all, there are hundreds of dividend-paying shares on the ASX, and trying to pick the right ones can be overwhelming. So to make the process...

The Abacus Property Group (ASX: ABG) share price is ending the week on a high. In morning trade, the ASX 200 real estate share is up 8% to $1.17. This follows the release of Abacus Property Group’s FY 2023 results. ASX 200 real estate sh...

Sydney-headquartered Imugene (ASX: IMU) has made a strong start to a $65 million capital raising aimed at supporting its global growth plans. The transformative cancer medicine developer has received firm commitments for the first phase of...

Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Imugene (IMU) receives firm commitments to raise $35 million through a share placement and will initiate an SSP for existing shareholders The placement comprises the issuance of 416.7 million new shares at 84 cents apiece, while the SSP...

The Imugene Limited (ASX: IMU) share price has returned from its trading halt and dropped deep into the red. At the time of writing, the immuno-oncology company’s shares are down 15% to 8 cents. Why is the Imugene share price sinking? Th...

Australian company Imugene (ASX:IMU) has agreed with US-based Precision Biosciences to acquire a worldwide exclusive license to its azer-cel allogeneic CD19 CAR-T cell therapy program.

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

After a steep early drop, the benchmark stabilised to close 1.5% down. InfoTech and Materials fared worst, following a mega tech sell-off on Wall Street. Loyal Lithium soared more than 37% after hitting fresh spod at Trieste.   I think we...

On Wednesday, the ASX experienced a significant drop in response to a global sell-off that took place overnight. At the closing bell, the S&P/ASX 200 was 1.5 per cent lower at 7,195.20. This decline was mirrored by the All Ordinaries in...

Imugene (IMU) enters an agreement with Precision Biosciences to acquire an exclusive worldwide license for the latter’s azer-cel allogeneic CD19 CAR T cell therapy program It gives the company the potential to initiate a registrational s...

We’re smack bang in the middle of ASX earnings season right now. And with earnings comes new dividend announcements from many S&P/ASX 300 Index (ASX: XKO) shares and by extension, ex-dividend dates. What does ex-dividend mean? Whenever...

  AML3D (ASX:AL3) has received a $2M order from US Navy for submarine parts. In response, interim CEO Sean Ebert said: “AML3D’s focus is on the US defence, aviation and maritime sectors and the company is well positioned to access the many...

China's shift towards deflation is causing concern in financial markets, yet some money managers suggest potential positive outcomes, as lower prices stemming from China's role as a major global producer could lead to reduced costs worldwid...

Clinical-stage immuno-oncology company Imugene (ASX: IMU) has entered into an agreement with US-based Precision Biosciences to acquire a worldwide licence to Precision’s azer-cel (azercabtagene zapreleucel) allogeneic CD19 CAR T cell therap...

Clinical-stage immuno-oncology company Imugene (ASX: IMU) has entered into an agreement with US-based Precision Biosciences to acquire a worldwide licence to Precision’s azer-cel (azercabtagene zapreleucel) allogeneic CD19 CAR T cell therap...

The money will be used to fund the acquisition of a license for Precision Biosciences’ azer-cel allogeneic cancer treatment.

Futures are predicting that the ASX will open lower this morning, following losses across Europe and Wall Street overnight, compounded by China’s troubling economic outlook. However, amid this backdrop, the US reported robust retail sale...

16 Aug 2023 - A snapshot of the stocks on the move, featuring AML3D (ASX:AL3), Imugene (ASX:IMU) and Loyal Lithium (ASX:LLI).

The ASX200 closed the day 0.86 per cent lower with almost all sectors in the red except communications, IT and energy. Helping boost the energy sector gains was Woodside Energy, up more than a per cent while Job hunting platform Seek gai...

It was a depressing start to the trading week for the S&P/ASX 200 Index (ASX: XJO) this Monday. Following on from Friday’s losses, ASX 200 investors stepped on the gas when it came to selling today. By the end of t...

With so many shares to choose from on the ASX, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading brokers have named...

A little-known ASX All Ords share is setting the bar high today. In afternoon trade on Monday, the All Ordinaries Index (ASX: XAO) is down 0.8%. But this ASX All Ords share is heading the other way, up 7% at the time of writing to $2.06...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a disappointing decline. The benchmark index is currently down 0.9% to 7,272.1 points. Four ASX shares that are not letting that hold them back a...

Imugene (IMU) VAXINIA trial is moving ahead to cohort four The company is effectively de-risking its product with each successful step forward in the phase one trial VAXINIA seeks to kill solid cancers in the body using a virus as op...

The Imugene Ltd (ASX: IMU) share price is leaping higher today. Shares in the S&P/ASX 200 Index (ASX: XJO) biotechnology company closed on Friday trading for 89 cents. During the lunch hour on Monday, shares are swapping hands for 94 c...

Anteris Tech’s DurAVR THV was implanted successfully in a procedure Imugene moves forward to cohort 4 in VAXINIA study MGC Pharma says CimetraA has no toxicology profile in large animals   Anteris’ DurAVR THV implanted successfully Anteri...

Clinical stage immuno-oncology company Imugene (ASX: IMU) has announced that a Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33-hNIS (Vaxinia) has cleared the cohort 3 intratumo...

Highlights Imugene’s VAXINIA MAST trial has cleared cohort 3 IT monotherapy dose escalation study. With this development, Imugene can recruit for IT cohort 4 of the monotherapy dose escalation. In cohort 4, VAXINA will be administered...

The Carsales.Com Ltd (ASX: CAR) share price is on the move on Monday. At the time of writing, the auto listings company’s shares are up over 5% to a 52-week high of $26.00. This follows the release of the company’s FY 2023 results this m...

Futures suggest the ASX will open in the red this morning, ahead of fresh ABS wage data, which will be released tomorrow, and July’s jobs report to follow on Thursday. Nonetheless, here are some ASX-listed companies with news out today:...

The Renascor Resources Ltd (ASX: RNU) share price is down 3.6% today despite another positive update. The shares are currently sitting at 14 cents apiece. They took a 23% dive yesterday despite the ASX mineral explorer announcing “compel...

The Renascor Resources Ltd (ASX: RNU) share price is down 21% over the past two days following an update on the mineral explorer’s proposed Siviour Battery Anode Material (BAM) project. Renascor Resources owns the Siviour Graphite Deposit...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Futures suggest the ASX will open lower today as investors contemplate the unexpected downgrade of the USA’s top-tier sovereign credit rating. Tech shares have reigned in ahead of earnings from Apple and Amazon, which are expected this F...

Whilst the prevalence of Artificial intelligence has boosted the US-tech sector, with the likes of Nvidia and C3.ai seeing their share prices increase by 219% and 265% respectively since the start of the year, Down Under, tech stock valuati...

LOS ALTOS, CA, USA, July 20, 2023/EINPresswire.com/ -- RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform • Collaboration will explore trans-arte...

Imugene (IMU) enters a strategic research collaboration with RenovoRx to optimise the delivery of its oncolytic virotherapy for the treatment of difficult-to-access tumours Using RenovoRx’ TAMP therapy, IMU will investigate the ability t...

Highlights Imugene has formed a partnership with clinical-stage biopharmaceutical firm – RenovoRx for its oncolytic virus therapy. The collaboration will assess the ability to administer the CF33 oncolytic virus technology with the TAM...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage immuno-oncology company Imugene (ASX: IMU) and US biopharmaceutical company RenovoRx Inc have formed a strategic research collaboration to optimise the...

World Overnight SPI Overnight 7286.00 + 2.00 0.03% S&P ASX 200 7323.70 + 39.90 0.55% S&P500 4565.72 + 10.74 0.24% Nasdaq Comp 14358.02 + 4.38 0.03% DJIA 35061.21 + 109.28 0.31% S&P500 VIX 13.76 + 0.46 3.46% US 10...